CB Juhl, M Hollingdal, J Sturis, G Jakobsen, H … - Diabetes, 2002 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential
interest for the treatment of type 2 diabetes. To evaluate actions of NN2211, a
long-acting GLP-1 derivative, we examined 11 patients with type 2 diabetes, ... Cited by 174 - Related articles - BL Direct - All 6 versions
- ►pubget.com [PDF] H Agersø, LB Jensen, B Elbrønd, P Rolan, M … - Diabetologia, 2002 - Springer Aims/hypothesis. Glucagon-like peptide-1 (GLP-1), a polypeptide hormone secreted
by the l-cells in the gastrointestinal tract, has shown promising effects as a
new treatment modality for patients with Type II (non-insulin-dependent) ... Cited by 167 - Related articles - BL Direct - All 5 versions
AM Chang, G Jakobsen, J Sturis, MJ Smith, CJ … - Diabetes, 2003 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion in a
glucose-dependent manner, but its short half-life limits its therapeutic
potential. We tested NN2211, a long-acting GLP-1 derivative, in 10 subjects ... Cited by 94 - Related articles - BL Direct - All 9 versions
- ►diabetesjournals.org KB Degn, CB Juhl, J Sturis, G Jakobsen, B … - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for
treating type 2 diabetes. We explored the effect of short-term (1 week)
treatment with a GLP-1 derivative, liraglutide (NN2211), on 24-h dynamics ... Cited by 168 - Related articles - BL Direct - All 8 versions
- ►diabetesjournals.org S Madsbad, O Schmitz, J Ranstam, G … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A double-blind, randomized, parallel-group,
placebo-controlled trial with an open-label comparator arm was conducted among
193 outpatients with type 2 diabetes. The mean age was 56.6 years and the ... Cited by 170 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org B Elbrønd, G Jakobsen, S Larsen, H Agersø, … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a double-blind, randomized dose, escalation,
placebo-controlled study, healthy male subjects were enrolled at eight
consecutive dose levels (1.25, 2.5, 5.0, 10.0, 12.5, 15.0, 17.5, and 20.0 ... Cited by 103 - Related articles - BL Direct - All 6 versions
- ►endojournals.org OG Kolterman, JB Buse, MS Fineman, E Gaines … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc Despite the advent of new treatments, glucose control in the type 2 diabetes
population is unsatisfactory. AC2993 (synthetic exendin-4; exenatide), a novel
glucose-dependent insulinotropic agent, exhibited notable antidiabetic ... Cited by 275 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org MS Fineman, TA Bicsak, LZ Shen, K Taylor, E … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—All three AC2993 regimens led to significant reductions in serum
fructosamine relative to placebo (P ≤ 0.004). Mean reductions ranged from 39
to 46 μmol/l. All AC2993 groups had reductions in HbA 1c ranging from 0.7 ... Cited by 230 - Related articles - BL Direct - All 10 versions
- Free from Publisher BO Ahrén, E Simonsson, H Larsson, M Landin … - Diabetes Care, 2002 - Am Diabetes Assoc OBJECTIVE—Glucagon-like peptide-1 (GLP-1) has been proposed as a new treatment
modality for type 2 diabetes. To circumvent the drawback of the short half-life
of GLP-1, inhibitors of the GLP-1–degrading enzyme dipeptidyl peptidase ... Cited by 274 - Related articles - BL Direct - All 7 versions
- ►physiology.org B Rolin, MO Larsen, CF Gotfredsen, CF … - American Journal of Physiology- Endocrinology And …, 2002 - Am Physiological Soc NN2211 is a long-acting, metabolically stable glucagon-like peptide-1 (GLP-1)
derivative designed for once daily administration in humans. NN2211 dose
dependently reduced the glycemic levels in ob/ob mice, with ... Cited by 129 - Related articles - BL Direct - All 4 versions
